TIDMHIK
RNS Number : 4898G
Hikma Pharmaceuticals Plc
12 May 2011
Hikma Pharmaceuticals PLC - Results of 2011 Annual General
Meeting
LONDON, 12 May 2011 - Hikma Pharmaceuticals PLC ("the Company")
advises that at its Annual General Meeting of shareholders, held at
The Westbury, Bond Street, Mayfair, London W1S 2YF that commenced
at 11:00 am today, 12 May 2011, all resolutions were passed on a
poll. Resolutions 1 to 7, 11 and 12 were passed as ordinary
resolutions and Resolutions 8 to 10 were passed as special
resolutions.
Copies of the resolutions dealing with special business passed
at the Annual General Meeting have been submitted to the UK Listing
Authority for publication through the Listing Authority's Document
Viewing Facility.
The total number of votes cast on the poll for each resolution
is set out below. The number of Ordinary Shares in issue on 12 May
2011 was 194,853,607
Votes Votes
Resolution Votes For % Against % Witheld
To receive
the 2010
report and
1 accounts 109,535,390 99.68% 350,635 0.32% 0
-------------- ------------ -------- ----------- ------- -----------
To declare a
final
2 dividend 109,886,025 100.00% 0 0.00% 0
-------------- ------------ -------- ----------- ------- -----------
Reappointment
of Said
3 Darwazah 109,466,109 99.62% 419,916 0.38% 0
-------------- ------------ -------- ----------- ------- -----------
Reappointment
of Deloitte
LLP as
4 auditors 108,091,702 98.37% 1,794,323 1.63% 0
-------------- ------------ -------- ----------- ------- -----------
Authorise the
directors to
set the
remuneration
of the
5 auditors 106,080,607 96.74% 3,575,022 3.26% 230,396
-------------- ------------ -------- ----------- ------- -----------
To receive
and approve
the
Remuneration
6 Report 107,926,101 99.14% 931,059 0.86% 1,028,865
-------------- ------------ -------- ----------- ------- -----------
Authorise the
directors to
7 allot shares 89,069,983 81.23% 20,585,696 18.77% 230,346
-------------- ------------ -------- ----------- ------- -----------
Disapply
pre-emption
8 rights 109,393,191 99.55% 492,834 0.45% 0
-------------- ------------ -------- ----------- ------- -----------
Authorise the
company to
buy back
9 shares 109,828,705 99.95% 56,820 0.05% 500
-------------- ------------ -------- ----------- ------- -----------
Authorise the
company to
call meetings
on 14 days
10 notice 105,617,616 96.12% 4,268,409 3.88% 0
-------------- ------------ -------- ----------- ------- -----------
Rule 9 waiver
for buy
11 backs 69,358,967 64.26% 38,579,215 35.74% 1,947,842
-------------- ------------ -------- ----------- ------- -----------
Rule 9 waiver
for LTIP &
12 MIP awards 69,835,487 64.70% 38,102,665 35.30% 1,947,872
-------------- ------------ -------- ----------- ------- -----------
Waiver of Rule 9 of the City Code on Takeovers and Mergers
In relation to Resolutions 11 and 12, at today's date, the total
number of ordinary shares held by the Concert Party, is 64,567,907
representing a combined shareholding of 33.14 per cent of the
issued share capital of the Company.
Assuming the Share Awards are made in respect of the full number
of shares referred to in the circular to shareholders dated 6 April
2011, that all such grants vest in full, and that all existing
awards LTIP Awards vest in full, and that all Options currently
held by members of the Concert Party were to be fully exercised and
the resulting Ordinary Shares retained by the Concert Party
members, the Concert Party would hold, in aggregate, interests over
65,238,707 Ordinary Shares, representing 33.37 per cent of the
issued share capital of the Company (as enlarged by the existing
LTIP and MIP Awards and Option Exercises by members of the Concert
Party and the issue of Ordinary Shares to members of the Concert
Party pursuant to the Share Awards, but assuming no other issue of
shares) versus 33.30 per cent of the issued share capital of the
Company on a similar basis, prior to the grant of such Share
Awards.
Were the Company to exercise the buy-back authority to the
exclusion of the Concert Party such that the Concert Party
maintained its current shareholding, that would result in the
Concert Party's percentage interest in the Company's issued share
capital increasing to 36.96 per cent. (assuming that all Existing
LTIP Awards vest in full and all Options held by members of the
Concert Party are exercised and the resulting Ordinary Shares are
retained, but not including the Share Awards granted under
Resolution 12).
If the maximum repurchase of Ordinary Shares authorised was
carried out by the Company and also the maximum number of Share
Awards vested, together with the Existing LTIP Awards and Option
Exercises these changes would increase the aggregate shareholding
of the Concert Party in the Company to 37.03 per cent. (assuming
that that the Concert Party did not sell any Ordinary Shares in the
repurchase of Ordinary Shares and assuming no other issue of
Ordinary Shares).
Declaration of final dividend
The final dividend of 7.5 cents per share will be paid on 26 May
2011 to shareholders on the register on 15 April 2011. Shareholders
who are not resident in Jordan have been given the option of
receiving their dividend in Pounds Sterling. The exchange rate in
respect of this dividend will be announced separately.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles
Company Secretary +44 20 7399 2670
Susan Ringdal
Investor Relations Director +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three
businesses: "Branded", "Injectables" and "Generics". Hikma's
operations are based principally in the Middle East and North
Africa ("MENA") region, where it is a market leader and sells
across 17 countries, the United States and Europe. In 2010, the
Group achieved revenues of $731 million (2009 $637 million) and
profit attributable to shareholders was $99 million (2009 $78
million).
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMSFWFFEFFSEFI
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
